[Invasive candidiasis in critically ill adult patient]

Area of Science:

• Infectious Diseases
• Critical Care Medicine
• Mycology

Context:

• Invasive Candida infections pose a significant threat to critically ill patients, contributing to high mortality rates.
• Despite advances in antifungal drugs, treatment challenges persist for various Candida strains, including non-albicans species.
• Early and accurate diagnosis is crucial for effective management of invasive candidiasis.

Purpose:

• To highlight the importance of early diagnosis and effective antifungal therapy for invasive Candida infections in critically ill patients.
• To discuss the role of echinocandins as a recommended empiric therapy based on international guidelines.
• To address the need for broad-spectrum antifungal coverage against diverse Candida strains.

Summary:

• Invasive Candida infections are a critical concern in intensive care settings, necessitating prompt identification and treatment.
• Current therapeutic strategies emphasize early empiric therapy with echinocandins due to their documented efficacy and safety profile against Candida albicans and non-albicans strains.
• The development of new echinocandins may enhance accessibility and affordability of these vital antifungal agents.

Impact:

• Improved clinical outcomes for critically ill patients with invasive candidiasis through timely and appropriate antifungal treatment.
• Potential for reduced mortality rates by implementing guideline-recommended empiric echinocandin therapy.
• Enhanced accessibility to effective antifungal treatments with the introduction of potentially lower-cost echinodandin options.